Compare BGX & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BGX | ACOG |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.2M | 110.4M |
| IPO Year | 2010 | N/A |
| Metric | BGX | ACOG |
|---|---|---|
| Price | $10.81 | $6.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 48.2K | 29.1K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.38 | $4.50 |
| 52 Week High | $12.65 | $10.88 |
| Indicator | BGX | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 59.70 |
| Support Level | $10.76 | $6.46 |
| Resistance Level | $10.97 | $6.89 |
| Average True Range (ATR) | 0.06 | 0.39 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 29.41 | 72.64 |
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The company's seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.